International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
a study on Gaucher Disease Glucocerebrosidase Deficiency Disease
Summary
- Location
- at UC Davis UC Irvine UCSD UCSF
- Dates
- study startedcompletion around
Description
Summary
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
- To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
- To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
- To characterize the Gaucher disease population.
- To evaluate the long-term effectiveness of imiglucerase and of eliglustat.
Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.
Official Title
Gaucher Disease Registry Protocol
Keywords
Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease, Lipidoses, Deficiency Diseases
Eligibility
You can join if…
ICGG Gaucher Registry
- All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and/or mutation in the β-glucocerebrosidase gene.
- For all patients, appropriate patient authorization will be obtained.
Gaucher Pregnancy Sub-registry:
- be enrolled in the ICGG Gaucher Registry.
- be pregnant, or have been pregnant with appropriate medical documentation available.
- provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.
You CAN'T join if...
- No exclusion criteria for participation in the ICGG Gaucher Registry and Sub-registry.
Locations
- University of California at Irvine- Site Number : 840036
accepting new patients
Irvine California 92617 United States - UC Davis MIND Institute- Site Number : 840010
accepting new patients
Sacramento California 95817 United States - University of California at San Diego- Site Number : 840007
completed
San Diego California 92093 United States - University of California at San Francisco- Site Number : 840051
accepting new patients
San Francisco California United States - Tower Hematology/Oncology Medical Group- Site Number : 840056
accepting new patients
Beverly Hills California 90211 United States - Southern California Permanente Medical Group- Site Number : 840108
accepting new patients
Los Angeles California 90027 United States - Children's Hospital of Orange County- Site Number : 840074
accepting new patients
Orange California 92868 United States - USC Health Sciences Center Dept of Genetics- Site Number : 840082
accepting new patients
Los Angeles California 90033 United States - Kaiser Permanente Hospital- Site Number : 840042
completed
Sacramento California 95825 United States - Stanford Unviersity MC Dept of Genetics- Site Number : 840022
accepting new patients
Palo Alto California 94305 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Genzyme, a Sanofi Company
- ID
- NCT00358943
- Study Type
- Observational [Patient Registry]
- Participants
- Expecting 12000 study participants
- Last Updated